Maleimide chemistry raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-16 and is reviewed periodically as new material appears.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
These ranged from deformed jaws to cyclopia. After decades of research, in the 1980s, the compound responsible for these deformities was identified as the alkaloid 11-deoxyjervine, later renamed to cyclopamine.
A qullqa (Quechua pronunciation: [ˈqʊʎˌqa] "deposit, storehouse"; (spelling variants: colca, collca, qolca, qollca) was a storage building found along roads and near the cities and political centers of the Inca Empire. These were large stone buildings with roofs thatched with "ichu" grass, or what is known as Peruvian feathergrass (Jarava ichu). To a "prodigious [extent] unprecedented in the annals of world prehistory" the Incas stored food and other commodities which could be distributed to their armies, officials, conscripted laborers, and, in times of need, to the populace. The uncertainty of agriculture at the high altitudes which comprised most of the Inca Empire was among the factors which probably stimulated the construction of large numbers of qullqas.
== Use in meat production == In 2026, China refused a shipment of Argentinian beef that tested positive for chloramphenicol and banned any future shipments from that major refrigerator. The antibiotic is banned in meat production in both China and Argentina.
It includes "intimidation, coercion, threats, humiliation, shouting, sarcasm, victimisation, terrorising, singling-out, malicious pranks, physical abuse, verbal abuse, emotional abuse, belittling, bad faith, harassment, conspiracy to harm, ganging-up, isolation, freezing-out, ostracisim, innuendo, rumour-mongering, disrespect, mobbing, mocking, victim-blaming and discrimination." It must be repeated, and if so the Fair Work Commission may make an order for the behaviour to cease and to be corrected, and must do so within 14 days. This does not, however, result in compensation, and cannot be done if the bully or the victim are no longer employed. Ideally, employers should also act by having an anti-bullying policy and training its supervisors and workforce to create a cohesive culture at work.
Sources: en.wikipedia.org
=== PlayStation 3 version === While the Windows and Xbox 360 versions of The Orange Box were developed and published by Valve, the development of the PlayStation 3 port was outsourced to the Electronic Arts studio EA UK. In an interview with Edge magazine before the game's release, Valve co-founder Gabe Newell commented, "I think the people who have The Orange Box on the PS3 are going to be happy with their game experience. We've done the PC and 360 versions here and EA has a team doing the PS3 version – and they'll make the PS3 version a good product; EA got the job done in putting a lot of people with PS3 experience on the project. But I think it's harder to get it to the same standard as the 360 and PC versions". Despite this, he noted that Valve will probably handle PlayStation 3 versions of its products in the future.
== Lifespan == Gastric pit cells are replaced every 2–4 days. This high rate of turnover is a protective mechanism designed to protect the epithelial lining of the stomach from both the proteolytic action of pepsin and the acid produced by parietal cells. Gastric chief cells are much longer lived and are believed to differentiate from stem cells located higher in the gastric unit in the isthmus. These stem cells differentiate into mucous neck cells in the isthmus and transition into chief cells as they migrate towards the base. Since the mucus neck cells do not divide as it becomes a chief cell this process is known as transdifferentiation. The gene Mist1 has been shown to regulate mucus neck cell to chief cell transdifferentiation and plays a role in the normal development of the chief cell organelles and structures.
== Applications == The covalent binding of the isopeptag to its binding partner can be used to permanently link proteins together in the complex environment of a bacterial cell, to target proteins of interest for cellular imaging, and to develop new protein structures.
Sources: en.wikipedia.org
=== Glue Library incident === In June 2022, the author of the popular Garry's Mod addons "Glue Library", "View Extension", "Action Extension", and "Ambient Occlusion" altered their work to display shock images such as goatse and play loud sounds. The addons' new source files contained curses directed at Newman, Valve co-founder Gabe Newell, and Steam moderators. According to PC Gamer, the files appeared to indicate the changes were a "deliberate prank" and not due to the addons being compromised. Another user changed their "Trollface Playermodel" addons to present the user with a different set of explicit images and slurs loudly played back in the voice of the cartoon character SpongeBob SquarePants.
=== Production of acrylonitrile === Currently, most acrylonitrile (90% in 2008) is produced by the SOHIO method, which is based on the catalytic oxidation of propylene in the presence of ammonia and bismuth phosphomolybdate. However, until 1960 a key production process was addition of hydrogen cyanide to ethylene oxide, followed by dehydration of the resulting cyanohydrin:
He is a practising barrister and jurist and teaches course on human rights at Hebrew University of Jerusalem; author of best selling book on International Law (first published in 1977; 6th edition released in 2008); also edited Title to Territory, a collection of articles on title and sovereignty in international law. His textbook is one of the key tomes used in introductory courses on international law. Shaw has appeared before the European Court of Human Rights, European Court of Justice, the UK Supreme Court, and the International Court of Justice (ICJ). Before the ICJ, he has represented countries such as the UAE, Serbia, and Cameroon. He has represented Azerbaijan, Ukraine, Ireland, and Malaysia in front of the other courts. In January 2024, he was on the four-person team representing Israel in the case brought by South Africa in the ICJ regarding accusations of genocidal acts by Israel in Gaza in the course of the Gaza war.
The European Wound Management Association (EWMA) was founded in 1991. The association promotes the advancement of education and research into native epidemiology, pathology, diagnosis, prevention and management of wounds of all aetiologies. EWMA is an umbrella organisation linking wound management associations across Europe and a multidisciplinary group bringing together individuals and organisations interested in wound management. Currently, the association bridges 54 Cooperating Organisations (national wound care associations in Europe) and, in addition, partners with a considerable number of wound and wound related associations in and outside of Europe. Similar organizations include the European Tissue Repair Society, the Tissue Viability Society, the World Union of Wound Healing Societies, and the Wound Care Society. EWMA is an educational resource, organising conferences, contributing to international projects related to wound management, supporting the implementation of existing knowledge within wound management, and providing information on all aspects of wound management.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.